Melius Pharma
PrivateLast Round
Series A
May 3, 2022
Est. Valuation
$4.66M
Total Funding Raised
$1.82M
Company Overview
Melius Pharma is a Swedish clinical-stage pharmaceutical company developing a therapy for Th2-associated refractory chronic cough (RCC).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Melius Pharma Comparables
Compare Melius Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Seyltx, Inc. | 83% | |
| Algernon Health Inc. | 80% | |
| NeRRe Therapeutics | 79% | |
Melius Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 3, 2022 |
Melius Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fåhraeus Startup and Growth | Series A |
| Linc AB | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 19, 2026
Monthly visitors increased 58% MoM.
- May 4, 2025
Monthly visitors grew 61% MoM, reaching 1.6K.
Melius Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Melius Pharma's valuation, stock price, and market status.